openPR Logo
Press release

Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials, and Companies 2024 (Updated)

04-18-2024 04:11 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Ewing Sarcoma Pipeline

Ewing Sarcoma Pipeline

DelveInsight's, "Ewing Sarcoma Pipeline Insights 2024" report provides comprehensive insights about 25+ Ewing Sarcoma companies and 25+ pipeline drugs in the Ewing Sarcoma pipeline landscape. It covers the Ewing Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ewing Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Ewing Sarcoma Pipeline Report
• DelveInsight's Ewing Sarcoma pipeline report depicts a robust space with 25+ Ewing Sarcoma companies working to develop 25+ pipeline therapies for Ewing Sarcoma treatment.
• The leading Ewing Sarcoma Companies working in the market include Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
• Promising Ewing Sarcoma Pipeline Therapies in the various stages of development includes Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.
• April 2024:- Shanghai Pharmaceuticals Holding Co., Ltd- The Efficacy and Safety of TK216 in Subjects With Relapsed or Refractory Ewing's Sarcoma:a Phase II Clinical Trial in China. This study is a multicenter, single-arm, open-label Phase II clinical trial evaluating TK216 in combination with vincristine in the treatment of relapsed or refractory Ewing sarcoma (ES) including Ewing's sarcoma family tumors (ESFTs).
• April 2024:- Eli Lilly and Company- A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Irinotecan and Temozolomide in Participants With Relapsed or Refractory Ewing's Sarcoma. The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolamide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.

Request a sample and discover the recent advances in Ewing Sarcoma Treatment Drugs @ Ewing Sarcoma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Ewing Sarcoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Ewing Sarcoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Ewing Sarcoma clinical trial landscape.

Ewing Sarcoma Overview
Ewing sarcoma is the second most common primary malignant bone tumor, mostly affecting adolescents in the second decade of their life, and it is a highly metastatic class of sarcoma. Despite the use of radiotherapy or surgery, historically, an estimated 85% to 90% of patients died within a few months from a metastasis.

Find out more about Ewing Sarcoma Treatment Landscape @ Drugs for Ewing Sarcoma Treatment- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Ewing Sarcoma Emerging Drugs Profile
• Vigil: Gradalis
• ONCT216: Oncternal Therapeutics
• SP-2577: Salarius Pharmaceuticals

Ewing Sarcoma Pipeline Therapeutics Assessment
There are approx. 25+ Ewing Sarcoma companies which are developing the Ewing Sarcoma therapies. The Ewing Sarcoma companies which have their Ewing Sarcoma drug candidates in the most advanced stage, i.e. Phase III include, Gradalis.

DelveInsight's Ewing Sarcoma pipeline report covers around 25+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Ewing Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Ewing Sarcoma Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Learn more about the emerging Ewing Sarcoma Pipeline Therapies @ Ewing Sarcoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Ewing Sarcoma Pipeline Report
• Coverage- Global
• Ewing Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ewing Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Ewing Sarcoma Companies- Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
• Ewing Sarcoma Pipeline Therapies- Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.

Dive deep into rich insights for new drugs for Ewing Sarcoma treatment, Visit @ Ewing Sarcoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Ewing Sarcoma Executive Summary
3. Ewing Sarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ewing Sarcoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Vigil: Gradalis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ONCT216: Oncternal Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SP-2577: Salarius Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. CLR 131: Cellectar Biosciences
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ewing Sarcoma Companies
21. Ewing Sarcoma Key Products
22. Ewing Sarcoma Unmet Needs
23. Ewing Sarcoma Market Drivers and Barriers
24. Ewing Sarcoma Future Perspectives and Conclusion
25. Ewing Sarcoma Analyst Views
26. Ewing Sarcoma Key Companies
27. Appendix

For further information on the Ewing Sarcoma pipeline therapeutics, reach out to Ewing Sarcoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/ewing-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Published Links-
https://www.hoyolab.com/article/27093025
https://www.kfz-betrieb.vogel.de/community/user/ybhardwaj
https://pad.funkwhale.audio/s/z1sjb2E6Z
https://swaay.com/u/daviddollareusa/about/
https://www.bestadsontv.com/profile/462518/Denny-Dones
https://manybooks.net/user/denny-dones
https://topbazz.com/germanydennydones
https://wibki.com/dennydones1
https://onlineghibli.com/tavern/members.php?mode=profile&userid=12548&boardid=1
https://www.undrtone.com/germanydennydon
https://solo.to/germanydennydones
https://app.geniusu.com/users/2455075
https://forum.alidropship.com/members/germanydennydones.50354/#about
https://pantip.com/profile/7306022#topics
https://pubhtml5.com/homepage/npvs/preview
https://doodleordie.com/profile/germanydennydones
https://www.rafabasa.com/author/germanydennydones/
https://www.tabletennisdaily.com/forum/members/germanydennydones.122613/#about
https://nhattao.com/members/user6331540.6331540/
https://thelittlenet.com/dennydonesgerman
http://demo.advised360.com/read-blog/154799
https://thehealthbridges.com/read-blog/19127
https://app.talkshoe.com/user/joneswilliam/about#google_vignette
https://www.vaca-ps.org/blogs/142022/The-Evolving-Landscape-of-Healthcare-Business-Consulting-Services
https://www.anobii.com/en/01d38d0b9694756e64/profile/activity
https://myanimelist.net/profile/dennydonesgerman
https://forum.pivx.org/threads/healthcare-business-consulting-services-navigating-complexity-in-modern-healthcare.2035/
https://pubhtml5.com/homepage/npvs/
https://b31.org.uk/author/anniesmith9/
https://fairygodboss.com/users/profile/Ix-vMa09gj/Annie-Smith
https://forum.completefrance.com/index.php?/topic/71194-key-areas-of-focus-in-healthcare-consulting-services/
https://educatorpages.com/site/kelleadvin/pages/blog?
https://offgridworld.com/author/anniejones9/
https://www.openhumans.org/member/me/
https://findpenguins.com/5zphebtv0zouo
http://jobs.emiogp.com/author/williamsmith9/
https://www.shippingexplorer.net/en/user/williamsmith9/88249
https://wakelet.com/@DennyDones813
https://startupxplore.com/en/person/denny-dones
https://www.nfpjobs.com.au/employers/1939365-delveinsight
https://community.hodinkee.com/members/dennydoness
https://jobs.mikeroweworks.org/employers/1930150-delveinsight
https://www.social-vape.com/read-blog/132516
https://codex.core77.com/users/dennydones9
https://www.newjerseyhunter.com/members/dennydones1.84566/#about
https://au.blurb.com/user/dennydones9?profile_preview=true
https://trabajo.merca20.com/author/kelleadvin/
https://www.atlasobscura.com/users/dennydones1
https://www.mixcloud.com/dennydones1/
https://www.designspiration.com/ybhardwaj/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials, and Companies 2024 (Updated) here

News-ID: 3468955 • Views:

More Releases from DelveInsight Business Research LLP

Addison's Disease Market Outlook Report 2032 |Akorn Operating Co., Amneal Pharmaceuticals Inc., Bristol Myers Squibb Co., Neurocrine Biosciences Inc., Hikma Pharmaceuticals Plc., Merck & Co., Novartis AG., Pfizer Inc
Addison's Disease Market Outlook Report 2032 |Akorn Operating Co., Amneal Pharma …
DelveInsight's "Addison's Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Addison's Disease, historical and forecasted epidemiology as well as the Addison's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Addison's Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Addison's Disease market size
Anemia In Chronic Kidney Disease Market Outlook Report 2032 | 3SBio, UBI Pharma and Disc Medicine
Anemia In Chronic Kidney Disease Market Outlook Report 2032 | 3SBio, UBI Pharma …
DelveInsight's "Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Anemia In Chronic Kidney Disease, historical and forecasted epidemiology as well as the Anemia In Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Anemia In Chronic Kidney Disease market report provides current treatment practices, emerging drugs, the market share of
Visceral Pain associated with GI disorders Market Outlook Report 2032 | Addex Therapeutics Ltd., AstraZeneca., Astellas Pharma, Allergan, Chromocell Corporation, Takeda, GIcare Pharma, AbbVie, Grunenthal GmbH
Visceral Pain associated with GI disorders Market Outlook Report 2032 | Addex Th …
DelveInsight's "Visceral Pain associated with GI disorders Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Visceral Pain associated with GI disorders, historical and forecasted epidemiology as well as the Visceral Pain associated with GI disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Visceral Pain associated with GI disorders market report provides current treatment practices, emerging drugs,
Glabellar Frown Lines Market Report Outlook 2032 | Allergan, Galderma, Merz Pharmaceuticals, Evolus, Revance Therapeutics, Hugel Inc.
Glabellar Frown Lines Market Report Outlook 2032 | Allergan, Galderma, Merz Phar …
DelveInsight's "Glabellar Frown Lines Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Glabellar Frown Lines, historical and forecasted epidemiology as well as the Glabellar Frown Lines market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Glabellar Frown Lines market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted

All 5 Releases


More Releases for Ewing

Ewing Sarcoma Market (2019-2028) Overview with Size, Patients Population, Total …
Ewing Sarcoma Market Synopsis: Global Ewing Sarcoma Market Insights, Epidemiology and Market Forecast studies the present scenario of market (with the base year being 2018), Key Cross Competition, and the growth prospects of global Ewing Sarcoma market for 2018-2028 definition of Ewing Sarcoma: Ewing sarcoma is a malignant small, round, blue cell tumor. It is a disease in which cancer cells are found in the bone or in soft tissue. The most common
Ewing Sarcoma Therapeutics - Pipeline Analysis Celgene, Novartis, Pfizer, MacroG …
Ewing sarcoma pipeline comprises approximately 29 drug candidates in different stages of development. Ewing sarcoma is a condition in which formation of cancer or tumor takes place in bones and soft tissues. The symptoms associated with Ewing sarcoma include pain as well as swelling in the chest, back, legs, pelvis and arms, lumps in arms, bone fracture, weight loss, loss of appetite, fatigue, malaise, etc. Download free report Sample at: https://www.psmarketresearch.com/market-analysis/ewing-sarcoma-therapeutics-pipeline-analysis/report-sample *Major companies
Research Focused On the Ewing Sarcoma Treatment Market Size & Share, Growth, Tre …
The report "Ewing Sarcoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025 ", has been prepared based on an in-depth market analysis with inputs from industry experts. The objectives of this study are as follows: To define, describe, and forecast the "Ewing Sarcoma Treatment" market by type, application, component, delivery model, end user, and region To provide detailed information regarding major factors influencing market growth (drivers,
Ewing Sarcoma Global Clinical Trials Review H2 2017
Summary: ReportsWeb.com published “Ewing Sarcoma Global Clinical Trials” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: "Ewing Sarcoma Industry Outlook to 2022-Market Forecasts for Liquefied Natural Gas (LNG), Oil Storage, Pipelines and Gas Processing", is a comprehensive report on midstream oil and gas industry in Algeria. The report provides details such as name,
Ewing Sarcoma Global Clinical Trials Status, Region and Phase Review, H2, 2017
To Understand the Pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Ewing Sarcoma Global Clinical Trials Review, H2, 2017, provides an overview of Ewing Sarcoma clinical trials scenario. This report provides top line data relating to the clinical trials on Ewing Sarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers
Ewing Sarcoma Global Clinical Market – Growth & Forecast to 2022 Including Key …
A new research document with title 'Ewing Sarcoma Global Clinical Trials Review, H2, 2017' covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions and important players/vendors such as Pharma Mar SA, Pfizer , NantWorks etc. The report will help user gain market insights, future trends and growth prospects of Review, H2, 2017 , “Ewing Sarcoma Global Clinical Trials Review, H2, 2017""